Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2016 2
2017 2
2018 4
2019 4
2020 7
2021 10
2022 8
2023 5
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Results by year

Filters applied: . Clear all
Page 1
A Role for PET/CT in Response Assessment of Malignant Pleural Mesothelioma.
Sandach P, Seifert R, Fendler WP, Hautzel H, Herrmann K, Maier S, Plönes T, Metzenmacher M, Ferdinandus J. Sandach P, et al. Among authors: metzenmacher m. Semin Nucl Med. 2022 Nov;52(6):816-823. doi: 10.1053/j.semnuclmed.2022.04.008. Epub 2022 May 24. Semin Nucl Med. 2022. PMID: 35624033 Review.
68Ga-SSO-120 PET for Initial Staging of Small Cell Lung Cancer Patients: A Single-Center Retrospective Study.
Kersting D, Sandach P, Sraieb M, Wiesweg M, Metzenmacher M, Darwiche K, Oezkan F, Bölükbas S, Stuschke M, Umutlu L, Nader M, Hamacher R, Fendler WP, Wienker J, Eberhardt WEE, Schuler M, Herrmann K, Hautzel H. Kersting D, et al. Among authors: metzenmacher m. J Nucl Med. 2023 Oct;64(10):1540-1549. doi: 10.2967/jnumed.123.265664. Epub 2023 Jul 20. J Nucl Med. 2023. PMID: 37474272
Favorable survival outcomes in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer sequentially treated with a tyrosine kinase inhibitor and osimertinib in a real-world setting.
Kraskowski O, Stratmann JA, Wiesweg M, Eberhardt W, Metzenmacher M, Schmid KW, Herold T, Schildhaus HU, Darwiche K, Aigner C, Stuschke M, Laue K, Zaun G, Kasper S, Hense J, Sebastian M, Schuler M, Pogorzelski M. Kraskowski O, et al. Among authors: metzenmacher m. J Cancer Res Clin Oncol. 2023 Sep;149(11):9243-9252. doi: 10.1007/s00432-023-04839-3. Epub 2023 May 18. J Cancer Res Clin Oncol. 2023. PMID: 37198447 Free PMC article.
Rebiopsy in advanced non-small cell lung cancer, clinical relevance and prognostic implications.
Scheffler M, Wiesweg M, Michels S, Nogová L, Kron A, Herold T, Scheel AH, Metzenmacher M, Eberhardt WE, Reis H, Fassunke J, Darwiche K, Aigner C, Schaufler D, Riedel R, Fischer R, Koleczko S, Schildhaus HU, Merkelbach-Bruse S, Schmid KW, Büttner R, Wolf J, Schuler M. Scheffler M, et al. Among authors: metzenmacher m. Lung Cancer. 2022 Jun;168:10-20. doi: 10.1016/j.lungcan.2022.04.006. Epub 2022 Apr 16. Lung Cancer. 2022. PMID: 35461051
Prognostic factors in nonsmall cell lung cancer: insights from the German CRISP registry.
Metzenmacher M, Griesinger F, Hummel HD, Elender C, Schäfer H, de Wit M, Kaiser U, Kern J, Jänicke M, Spring L, Zacharias S, Kaiser-Osterhues A, Groth A, Hipper A, Zaun G, Dörfel S, Güldenzoph B, Müller L, Uhlig J, Thomas M, Sebastian M, Eberhardt WEE; CRISP Registry Group. Metzenmacher M, et al. Eur Respir J. 2023 Feb 2;61(2):2201336. doi: 10.1183/13993003.01336-2022. Print 2023 Feb. Eur Respir J. 2023. PMID: 36180086 Free PMC article.
Prediction of malignant lymph nodes in NSCLC by machine-learning classifiers using EBUS-TBNA and PET/CT.
Guberina M, Herrmann K, Pöttgen C, Guberina N, Hautzel H, Gauler T, Ploenes T, Umutlu L, Wetter A, Theegarten D, Aigner C, Eberhardt WEE, Metzenmacher M, Wiesweg M, Schuler M, Karpf-Wissel R, Santiago Garcia A, Darwiche K, Stuschke M. Guberina M, et al. Among authors: metzenmacher m. Sci Rep. 2022 Oct 20;12(1):17511. doi: 10.1038/s41598-022-21637-y. Sci Rep. 2022. PMID: 36266403 Free PMC article.
[68Ga]FAPI-PET/CT for radiation therapy planning in biliary tract, pancreatic ductal adeno-, and adenoidcystic carcinomas.
Guberina N, Kessler L, Pöttgen C, Guberina M, Metzenmacher M, Herrmann K, Mucha M, Rischpler C, Indenkämpen F, Siveke JT, Treckmann J, Umutlu L, Kasper S, Fendler WP, Stuschke M. Guberina N, et al. Among authors: metzenmacher m. Sci Rep. 2022 Sep 28;12(1):16261. doi: 10.1038/s41598-022-20447-6. Sci Rep. 2022. PMID: 36171444 Free PMC article.
Effectiveness of durvalumab consolidation in stage III non-small-cell lung cancer: focus on treatment selection and prognostic factors.
Guberina M, Guberina N, Pöttgen C, Gauler T, Richlitzki C, Metzenmacher M, Wiesweg M, Plönes T, Forsting M, Wetter A, Herrmann K, Hautzel H, Darwiche K, Theegarten D, Aigner C, Schuler M, Stuschke M, Eberhardt WE. Guberina M, et al. Among authors: metzenmacher m. Immunotherapy. 2022 Aug;14(12):927-944. doi: 10.2217/imt-2021-0341. Epub 2022 Jul 13. Immunotherapy. 2022. PMID: 35822656 Free article. Clinical Trial.
39 results